The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options

Sunday, November 12
6:30 pm – 9:30 pm

This live symposium will focus on the role of lipoprotein(a) and its therapeutic options for patients with cardiovascular disease. A review of the science of Lp(a) and its role in the management and prevention of cardiovascular risk will be discussed. The expert faculty will examine clinical trial data and mechanisms of action of emerging therapeutics to reduce Lp(a). Information regarding how to apply emerging science into individualized treatment strategies to optimally manage Lp(a) and improve cardiovascular outcomes will be reviewed. The educational material of this symposium will provide crucial information for cardiologist to improve outcomes in patients with cardiovascular disease.

Applying PCSK9 Inhibitors to Optimize Outcomes in Patients with Dyslipidemia

Monday, November 13
6:30 pm – 9:30 pm

This live symposium will highlight optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. The five expert faculty will review recent clinical trial and CVD outcomes data, encompassing data on lipid lowering therapies for the diabetes subgroup.  Dyslipidemia guidelines and strategies for achieving LDL-C goal will be outlined, particularly for the high-risk patient. Dr. Christopher Cannon and the accompanying faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision making. The education presented at this symposium will provide vital information for the cardiologist to improve healthcare outcomes in patients with dyslipidemia.

Register Now